Add Sanofi to the list of drugmakers committing billions to bolster their operations in the United States as President Donald Trump continues to ramp up pressure on the biopharma industry.
On Wednesday, Sanofi said it will invest at least $20 billion through 2030 to beef up its R&D and manufacturing operations in the U.S.
The Paris-based company said it will expand its manufacturing capacity at its current U.S. sites and will enhance its partnerships with other domestic manufacturers to help “ensure the production of medicines in the U.S.” The increased investment will “create a significant number of high-paying jobs in multiple states,” Sanofi added.
“Sanofi's 13,000 U.S.-based employees are pioneering the research and development of first- and best-in-class medicines across numerous therapeutic areas,” Sanofi CEO Paul Hudson, said in a release.
The company’s global headcount entering this year was 83,000. In 2024, of its net sales of 41.8 billion euros ($45.2 billion), 20 billion euros ($21.6 billion) came from the U.S.
With the plan, Sanofi joins other pharma giants such as Eli Lilly, Johnson & Johnson, Gilead Sciences and Novartis, which have each touted their U.S. investment plans in recent weeks.
Also on Wednesday, Roche, which revealed three weeks ago its commitment to spend $50 billion in the U.S. over the next five years, said it was open to reconsidering its pledge after Trump signed an Executive Order on Monday aiming to slash drug prices in the U.S. based on a “Most Favored Nation” pricing scheme.
“Should the proposed Executive Order go into effect, Roche’s ability to fund the significant investments previously announced in the U.S. will be in question,” a spokesperson said via email. “Overall, we are concerned that the Executive Order will undermine the U.S.’s position as the world’s leading pharmaceutical and healthcare ecosystem, as well as dampen economic growth and lead to job losses in the U.S.”
In a press conference before signing the Executive Order, Trump praised pharma companies that have announced their plans to increase their investments in the U.S., hinting that he may be abandoning his threat to levy pharma-specific tariffs on drug imported into the U.S.